Release of soluble IL-6 receptor (IL-6sR) in comparison with release of soluble TNF receptors (sTNF-Rs) by PMNs and WBC derived from breast cancer patients
- PMID: 18372525
- DOI: 10.1016/s0304-3835(97)00256-5
Release of soluble IL-6 receptor (IL-6sR) in comparison with release of soluble TNF receptors (sTNF-Rs) by PMNs and WBC derived from breast cancer patients
Abstract
Soluble cytokine receptors are more general phenomena and play a wider physiological role in the regulation of the immune system than previously recognized. Soluble IL-6 receptor (IL-6sR) and soluble TNF receptors (sTNF-Rs) might play a regulatory role in a variety of normal and abnormal reactions mediated by IL-6 and TNF-alpha. The release of IL-6sR and sTNF-Rs by polymorphonuclear cells (PMNs) of breast cancer patients in vitro was measured. The results obtained were compared to the secretion of these soluble receptors by whole blood cells (WBC). We found that PMNs of patients examined secreted the concentrations of IL-6sR as in healthy subjects. Simultaneously, significantly higher values of sTNF-RI and sTNF-RII released by PMNs of patients were measured in comparison with the values of the control group. The mean concentrations of IL-6sR and sTNF-Rs secreted by WBC of control and cancer groups were higher than those released by PMNs. Altered secretion of sTNF-Rs and no altered secretion of IL-6sR by PMNs of breast cancer patients may have various implications for response to malignancy.
Similar articles
-
The ability of human polymorphonuclear cells (PMNS) to release of soluble IL-6 receptor (IL-6sR) in response to different stimuli in vitro.Rocz Akad Med Bialymst. 1997;42(1):89-98. Rocz Akad Med Bialymst. 1997. PMID: 9581468
-
Release of soluble tumor necrosis factor receptors from polymorphonuclear cells of breast cancer patients.Arch Immunol Ther Exp (Warsz). 1997;45(5-6):449-53. Arch Immunol Ther Exp (Warsz). 1997. PMID: 9437501
-
Changes in sIL-6R and sTNF-Rs release by PMNs and the serum levels in breast cancer patients at different stages of treatment.Cytokine. 1998 Jul;10(7):540-3. doi: 10.1006/cyto.1997.0327. Cytokine. 1998. PMID: 9702418
-
[Soluble TNF-alpha receptors].Postepy Hig Med Dosw. 1997;51(5):567-75. Postepy Hig Med Dosw. 1997. PMID: 9489455 Review. Polish.
-
Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis.Eur J Haematol. 1995 Jan;54(1):1-8. doi: 10.1111/j.1600-0609.1995.tb01618.x. Eur J Haematol. 1995. PMID: 7859870 Review.
Cited by
-
Optimizing the time of Doxil injection to increase the drug retention in transplanted murine mammary tumors.Int J Nanomedicine. 2010 Apr 7;5:221-9. doi: 10.2147/ijn.s8488. Int J Nanomedicine. 2010. PMID: 20463938 Free PMC article.
-
TGF-beta1 influence on TNF-alpha production and sTNF-Rs shedding in a coculture of colon carcinoma cell spheroids with normal cells.In Vitro Cell Dev Biol Anim. 2009 Jul-Aug;45(7):371-7. doi: 10.1007/s11626-009-9190-9. Epub 2009 Mar 20. In Vitro Cell Dev Biol Anim. 2009. PMID: 19301076
-
Targeting TNFR2 for cancer immunotherapy: recent advances and future directions.J Transl Med. 2024 Sep 2;22(1):812. doi: 10.1186/s12967-024-05620-x. J Transl Med. 2024. PMID: 39223671 Free PMC article. Review.
-
Clinical implications of tumor necrosis factor receptor 2 in breast cancer.Oncol Lett. 2017 Aug;14(2):2393-2398. doi: 10.3892/ol.2017.6410. Epub 2017 Jun 19. Oncol Lett. 2017. PMID: 28789455 Free PMC article.
-
A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study.Pediatr Blood Cancer. 2011 Aug;57(2):275-82. doi: 10.1002/pbc.22821. Epub 2010 Nov 12. Pediatr Blood Cancer. 2011. PMID: 21671363 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical